Alopecia Clinical Trial
Official title:
Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in the Treatment of Central Centrifugal Cicatricial Alopecia
The purpose of this study is to ascertain the safety and efficacy of
Clobetasol Propionate 0.05% E Foam in the treatment of Central Centrifugal
Cicatricial Alopecia.
Central Centrifugal Cicatricial Alopecia (CCCA) is an inflammation-induced
hair loss starting in the central scalp and progressing centrifugally. The
cause of CCCA is unknown. Early diagnosis and treatment is essential to stop
or slow the progression of scarring and permanent hair loss. Once scarring
occurs, the hair follicles are obliterated and the hair cannot regrow. Thus,
anti-inflammatory medications are used to decrease inflammation. Current
treatment includes topical and intralesional corticosteroids, oral
antibiotics, and hair transplantation, all which may take months to years to
show improvement. There is no evidence-based medicine on how to treat
primary cicatricial alopecias. Clobestasol Propionate 0.05% Emollient Foam is
an FDA-approved and marketed topical corticosteroid for the treatment of the
inflammatory and pruritic manifestations of moderate to severe corticosteroid-
responsive dermatoses of the scalp. Many studies found the foam to be less
irritating than the original formulation.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04953416 -
Fractional Non-ablative Laser for the Treatment of Hair Loss
|
N/A | |
| Completed |
NCT01929330 -
Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers
|
Phase 1 | |
| Recruiting |
NCT05213936 -
Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color
|
N/A | |
| Completed |
NCT02919735 -
Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)
|
Phase 2 | |
| Recruiting |
NCT02591823 -
Hair Fall in Patients on Low Dose Methotrexate
|
N/A | |
| Enrolling by invitation |
NCT01651689 -
Hair Counts From Vertical and Horizontal Sections of Scalp Biopsy SPecimens in Thai Population With Alopecia
|
N/A | |
| Completed |
NCT01189279 -
Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia
|
Phase 1 | |
| Terminated |
NCT01385839 -
Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata
|
N/A | |
| Active, not recruiting |
NCT03382184 -
Fractional Photothermolysis for Hair Follicle Induction
|
Early Phase 1 | |
| Not yet recruiting |
NCT05544448 -
In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases
|
N/A | |
| Completed |
NCT03689452 -
The Effect of Platelet Rich Plasma on Non-scarring Alopecia
|
N/A | |
| Completed |
NCT06409650 -
To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia
|
Phase 2 | |
| Recruiting |
NCT00801086 -
Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain
|
Phase 2 | |
| Completed |
NCT06095739 -
Study to Investigate the Effectiveness of a Topical Cosmetic Formulation DA-OTC-002
|
N/A | |
| Completed |
NCT05587699 -
The Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A
|
Phase 1 | |
| Completed |
NCT03351322 -
ENERGI-F701 for Female Hair Loss Treatment
|
Phase 2 | |
| Completed |
NCT01590238 -
Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM)
|
Phase 3 | |
| Not yet recruiting |
NCT01557491 -
Hair Regrowth After Bicoronal Incision
|
N/A | |
| Terminated |
NCT02935569 -
Compression Headband Use to Prevent Hair Loss During Whole Brain Radiotherapy
|
N/A | |
| Completed |
NCT00515762 -
Prevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling
|
Phase 2 |